Chlamydia pneumoniae and atherosclerosis

Cellular Microbiology

Volumn 6, Issue 2, 2004, Pages 117-127

  Belland, Robert J ^a   Ouellette, Scot P ^a   Gieffers, Jens ^b   Byrne, Gerald I ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIUM ANTIBODY; CYTOKINE; PLACEBO; PROCOAGULANT; ROXITHROMYCIN;

ANIMAL MODEL; ARTERY MUSCLE; ATHEROSCLEROSIS; BACTERIAL GENETICS; BACTERIUM CULTURE; BACTERIUM DETECTION; CARDIOVASCULAR DISEASE; CELL TYPE; CHLAMYDOPHILA PNEUMONIAE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE MODEL; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; EXPOSURE; FOAM CELL; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEOMICS; RABBIT; RESPIRATORY TRACT INFECTION; REVIEW; SECONDARY PREVENTION; SEROEPIDEMIOLOGY; SMOOTH MUSCLE FIBER; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIOSCLEROSIS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DISEASE MODELS, ANIMAL; HUMANS; MICE; RABBITS; RISK FACTORS;

ANIMALIA; BACTERIA (MICROORGANISMS); CHLAMYDIA; CHLAMYDOPHILA PNEUMONIAE; ORYCTOLAGUS CUNICULUS;

EID: 1642431985     PISSN: 14625814     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1462-5822.2003.00352.x     Document Type: Review

References (89)

1. Anderson, J.L., and Muhlestein, J.B. (2000) The ACADEMIC study in perspective (Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia). J Infect Dis 181 (Suppl. 3): S569-S571.
2. Anderson, J.L., Muhlestein, J.B., Carlquist, J., et al. (1999) Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 99: 1540-1547.
3. Bannantine, J.P., Griffiths, R.S., Viratyosin, W., Brown, W.J., and Rockey, D.D. (1999) A secondary structural motif predictive of protein localization to the chlamydial inclusion membrane. Cell Microbiol 2: 35-48.
4. Beatty, W.L., Morrison, R.P., and Byrne, G.I. (1994) Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 58: 686-699.
5. Biasucci, L.M., Liuzzo, G., Ciervo, A., Petrucca, A., Piro, M., Angiolillo, D.J., et al. (2003) Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes. Circulation 107: 3051-3057.
6. Blasi, F., Denti, F., Erba, M., et al. (1996) Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol 34: 2766-2769.
7. de Boer, O.J., van der Wal, A.C., Houtkamp, M.A., Ossewaarde, J.M., Teeling, P., and Becker, A.E. (2000) Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae. Cardiovasc Res 48: 402-408.
8. Byrne, G. I., and Kalayoglu, M.V. (1999) Chlamydia pneumoniae and atherosclerosis: links to the disease process. Am Heart J 138: S488-S490.
9. Campbell, L.A., Blessing, E., Rosenfeld, M., Lin, T., and Kuo, C. (2000) Mouse models of C. pneumoniae infection and atherosclerosis. J Infect Dis 181 (Suppl. 3): S508-S513.
10. Ciervo, A., Visca, P., Petrucca, A., Biasucci, L.M., Maseri, A., and Cassone, A. (2002) Antibodies to 60-kilodalton heat shock protein and outer membrane protein 2 of Chlamydia pneumoniae in patients with coronary heart disease. Clin Diagn Lab Immunol 9: 66-74.
11. Coles, A.M., Reynolds, D.J., Harper, A., Devitt, A., and Pearce, J.H. (1993) Low-nutrient induction of abnormal chlamydial development: a novel component of chlamydial pathogenesis? FEMS Microbiol Lett 106: 193-200.
12. Coombes, B.K., and Mahoney, J.B. (1999) Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). Infect Immun 67: 2909-2915.
13. Dechend, R., Maass, M., Geiffers, J., Dietz, R., Scheidereit, C., Lentz, A., and Galba, D.C. (1999) Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated atherosclerosis. Circulation 100: 1369-1373.
14. Dunne, M.W. (2000) Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial. J Infect Dis 181 (Suppl. 3): S572-S578.
15. Fong, I.W. (2000) Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis. J Infect Dis 181 (Suppl. 3): S514-S518.
16. Fong, I.W., Chiu, B., Viira, E., Fong, M.W., Jang, D., and Mahoney, J.B. (1997) Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 35: 48-52.
17. Fong, I.W., Chui, B., Viira, E., Tucker, W., Wood, H., and Peeling, R.W. (2002) Chlamydial heat-shock protein-60 antibody and correlation with Chlamydia pneumoniae in atherosclerotic plaques. J Infect Dis 186: 1469-1473.
18. Fryer, R.H., Schobe, E.P., Woods, M.L., and Rodgers, G.M. (1997) Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Invest Med 45: 168-174.
19. Gaydos, C.A., (2000) Growth in vascular cells and cytokine production by Chlamydia pneumoniae. J Infect Dis 181 (Suppl. 3): S473-S478.
20. Gaydos, C.A., Summersgill, J.T., Sahney, N.A., Ramirez, J.A., and Quinn, T.C. (1996) Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells and aortic artery smooth muscle cells. Infect Immun 64: 1614-1620.
21. Geng, Y., Shane, R.B., Berencsi, K., et al. (2000) Chlamydia pneumoniae inhibits apoptosis in human peripheral blood mononuclear cells through induction of IL-10. J Immunol 164: 5522-5529.
22. Gieffers, J., Fullgraf, H., Jahn, J., Klinger, M., Dalhoff, K., Katus, H.A., et al. (2001) Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 103: 351-356.
23. Gieffers, J., Belland, R.J., Whitmire, W., Oullette, S., Crane, D., Maass, M., et al. (2002) Isolation of Chlamydia pneumoniae clonal variants by a focus-forming assay. Infect Immun 70: 5827-5834.
24. Gieffers, J., Durling, L., Oullette, S.P., Rupp, J., Maass, M., Byrne, G.I., et al. (2003) Genotypic differences in the Chlamydia pneumoniae tyrP locus related to vascular tropism and pathogenicity. J Infect Dis 188: 1085-1093.
25. Grayston, J.T. (1998) Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events. In Proceedings of the 9th International Symposium on Human Chlamydial Infection. Stephens, R., Byrne, G., Christiansen, G., et al. (eds). San Francisco: International Chlamydia Symposium, pp. 187-190.
26. Grayston, J.T. (2000) Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 181 (Suppl. 3): S401-S410.
27. Gupta, S., Leatham, E.W., Carrington, D., Mendall, M.A., Kaski, J.C., and Camm, A.J. (1997) Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 96: 404-407.
28. Gurfinkel, E., Bozovich, G., Daroca, A., Beck, E., and Mautner, B. (1997) Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 350: 404-407.
29. Hackstadt, T., Rockey, D.D., Heinzen, R.A., and Scidmore, M.A. (1996) Chlamydia trachomatis interrupts an exocytic pathway to acquire endogenously synthesized sphingomyelin in transit from golgi apparatus to the plasma membrane. EMBO J 15: 964-977.
30. Hackstadt, T., Fischer, E.R., Scidmore, M.A., Rockey, D.D., and Heinzen, R.A. (1997) Origins and functions of the chlamydial inclusion. Trends Microbiol 5: 288-293.
31. Hahn, D.L., and Golubjatnikov, R. (1992) Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. Arterioscler Thromb 12: 945-947.
32. Hahn, D.L., Azenabor, A.A., Beatty, W.L., and Byrne, G.I. (2002) Chlamydia pneumoniae as a respiratory pathogen. Front Biosci 7: e66-76.
33. Halme, S., Juvonen, T., Laurila, A., et al. (1999) Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms. Eur J Clin Invest 29: 546-552.
34. Hammerschlag, M.R., and Vuletin, J.C. (1985) Ultrastructural analysis of the effect of trimethoprim and sulfamethoxazole on the development of Chlamydia trachomatis in cell culture. J Antimicrob Chemother 15: 209-217.
35. Hanna, L., Dawson, C., Briones, O., Thygeson, P., and Jawetz, E. (1968) Latency in human infections with TRIC agents. J Immunol 101: 43-50.
36. Haranaga, S., Yamaguchi, H., Friedman, H., Izumi, S.I., and Yamamoto, Y. (2001) Chlamydia pneumoniae infects and multiplies in lymphocytes in vitro. Infect Immun 69: 7753-7759.
37. Hsia, R.C., Pannekoek, Y., Ingerwski, E., and Bavoil, P.M. (1997) Type III secretion genes identify a putative virulence locus of Chlamydia. Mol Microbiol 25: 351-359.
38. Hu, H., Pierce, G.N., and Zhong, G. (1999) The atherogenic effects of Chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 103: 747-753.
39. Huittinen, T., Leinonen, M., Tenkanen, L., Manttari, M., Virkkunen, H., Pitkanen, T., et al. (2002) Autoimmunity to human heat shock protein 60, Chlamydia pneumoniae infection, and inflammation in predicting coronary risk. Aterioscler Thromb Vasc Biol 22: 431-437.
40. Jackson, L.A. (2000) Description and status of the azithromycin and coronary events study (ACES). J Infect Dis 181 (Suppl. 3): S579-S581.
41. Jackson, L.A., Campbell, L.A., Schmidt, R.A., et al. (1997) Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 150: 1785-1790.
42. Jahn, H.U., Krull, M., Wuppermann, F.N., Klucken, A.C., Rosseau, S., Seybold, J., et al. (2000) Infection and activation of airway epithelial cells by Chlamydia pneumoniae. J Infect Dis 182: 1678-1687.
43. Kalayoglu, M.V., and Byrne, G.I. (1998a) Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 177: 725-729.
44. Kalayoglu, M.V., and Byrne, G.I. (1998b) A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immun 66: 5067-5072.
45. Kalayoglu, M.V., Miranpuri, G.S., Golenbock, D.T., and Byrne, G.I. (1999a) Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae. Microbes Infect 1: 409-418.
46. Kalayoglu, M.V., Hoerneman, B., LaVerda, D., Morrison, S.G., Morrison, R.P., and Byrne, G.I. (1999b) Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis 180: 780-790.
47. Kalayoglu, M.V., Indrawati, Morrison, R.P., Morrison, S.G., Yuan, Y., and Byrne, G.I. (2000) Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect Dis 181 (Suppl. 3): S483-S489.
48. Kalman, S., Mitchel, W., Marathe, R., Lammel, C., Fan, J., Hyman, R.W., et al. (1999) Comparative genomes of Chlamydia pneumoniae and C. trachomatis. Nature Genet 21: 385-389.
49. Kaukoranta-Tolvanen, S.S., Teppo, A.M., Laitinen, K., Saikku, P., Linnavuori, K., and Leinonen, M. (1996) Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog 21: 215-221.
50. Kaul, R., Uphoff, J., Wideman, J., Yadlapalli, S., and Wenman, W.M. (2000) Detection of Chlamydia pneumoniae DNA in CD3+ lymphocytes from healthy blood donors and patients with coronary artery disease. Circulation 102: 2341-2346.
51. Kol, A., Sukhova, G.K., Lichtman, A.H., and Libby, P. (1998) Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha nad matrix metalloproteinase expression. Circulation 98: 300-307.
52. Kothe, H., Dalhoff, K., Rupp, J., et al. (2000) Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 101: 1760-1763.
53. Kuo, C.C., Shor, A., Campbell, L.A., Fukushi, H., Patton, D.L., and Grayston, J.T. (1993a) Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 167: 841-849.
54. Kuo, C.C., Gown, A.M., Benditt, E.P., and Grayston, J.T. (1993b) Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb 13: 1501-1504.
55. Kuo, C.C., Grayston, J.T., Campbell, L.A., Goo, Y.A., Wissler, R.W., and Benditt, E.P. (1995) Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci USA 92: 6911-6914.
56. Laitinen, K., Laurila, A., Pyhala, L., Leinonen, M., and Saikku, P. (1997) Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 65: 4832-4835.
57. Lin, T.M., Campbell, L.A., Rosenfeld, M.E., and Kuo, C.C. (2000) Monocyte-endothelial cell coculture enhances infection of endothelial cells with Chlamydia pneumoniae. J Infect Dis 181: 1096-1100.
58. Liuba, P., Karnani, P., Pesonen, E., et al. (2000) Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice. Circulation 102: 1039-1044.
59. McMillan, G. (1995) Historical review of research on atherosclerosis. Adv Exp Med Biol 369: 1-6.
60. Maass, M., Jahn, J., Gieffers, J., Dalhoff, K., Katus, H.A., and Solbach, W. (2000) Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction. J Infect Dis 181 (Suppl. 3): S449-S451.
61. Mahdi, S., Horne, B.D., Mullen, K., Muhlestein, J.B., and Byrne, G.I. (2002) Serum immunoglobulin G antibodies to chlamydial heat shock protein 60 but not human and bacterial homologs are associated with coronary artery disease. Circulation 106: 1659-1663.
62. Matsumoto, A., and Manire, G.P. (1970) Electron microscopic observations on the effects of penicillin on the morphology of Chlamydia psittaci. J Bacteriol 101: 278-285.
63. Mayr, M., Metzler, B., Kiechl, S., Willeit, J., Schett, G., Xu, Q., and Wick, G. (1999) Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae. Immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 99: 1560-1566.
64. Mehta, S.J., Miller, R.D., Ramirez, J.A., and Summersgill, J.T. (1998) Inhibition of Chlamydia pneumoniae replication in HEp-2 cells by interferon-g: role of tryptophan catabolism. J Infect Dis 177: 1326-1331.
65. Meyer, K. F., and Eddie, B. (1933) Latent psittacosis infection in shell parakeets. Proc Soc Exp Biol Medical 30: 483-488.
66. Miller, S.A., Selzman, C.H., Shames, B.D., Barton, H.A., Johnson, S.M., and Harken, A.H. (2000) Chlamydia pneumoniae activates nuclear factor kappaB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation. J Surg Res 90: 76-81.
67. Moazed, T.C., Kuo, C.C., Grayston, J.T., and Campbell, L.A. (1997) Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 175: 883-890.
68. Moazed, T.C., Kuo, C.C., Grayston, J.T., and Campbell, L.A. (1998) Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis 177: 1322-1325.
69. Molestina, R.E., Miller, R.D., Ramirez, J.A., and Summersgill, J.T. (1999) Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes. Infect Immun 67: 1323-1330.
70. Mosorin, M., Surcel, H.M., Laurila, A., et al. (2000) Detection of Chlamydia pneumoniae-reactive T lymphocytes in human atherosclerotic plaques of carotid artery. Arterioscler Thromb Vasc Biol 20: 1061-1067.
71. Muhlestein, J.B. (2000) Chlamydia pneumoniae-induced atherosclerosis in a rabbit model. J Infect Dis 181 (Suppl. 3): S505-S507.
72. Muhlestein, J.B., Hammond, E.H., Carlquist, J.F., et al. (1996) Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 27: 1555-1561.
73. Muhlestein, J.B., Anderson, J.L., Hammond, E.H., et al., (1998) Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 97: 633-636.
74. Muhlestein, J.B., Anderson, J.L., Carlquist, J.F., et al. (2000) Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 102: 1755-1760.
75. Netea, M.G., Selzman, C.H., Kullberg, B.J., et al. (2000) Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur J Immunol 30: 541-549.
76. Ong, G., Thomas, B.J., Mansfield, A.O., Davidson, B.R., and Taylor-Robinson, D. (1996) Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol 49: 102-106.
77. Peeling, R.W., Wang, S.P., Grayston, J.T., et al. (2000) Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results. J Infect Dis 181 (Suppl. 3): S426-S429.
78. Quinn, T. (1998) Does Chlamydia pneumoniae cause coronary heart disease? Curr Opin Infect Dis 11: 301-307.
79. Ramirez, J.A. (1996) Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med 125: 979-982.
80. Read, T.O., Brunham, R.C., Chen, C., et al. (2000) Genome sequence of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucleic Acids Res 28: 1397-1406.
81. Rebic, R., Nastic-Miric, D., Pavlovic, S., Pokrajcic, Z., and Bosnjakovic, V. (1993) Measuring of cardiolipin antibodies and plasma lipids in different stages of coronary disease. Med Pregl 46: 20-22.
82. Ross, R. (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-126.
83. Shemer-Avni, Y., and Lieberman, D. (1995) Chlamydia pneumoniae-induced ciliostasis in ciliated bronchial epithelial cells. J Infect Dis 171: 1274-1278.
84. Shirai, M., Hirakawa, H., Kimoto, M., et al. (2000) Comparison of whole genome sequences of Chlamydia pneumoniae J138 from Japan and CWL029 from USA. Nucleic Acids Res 28: 2311-2314.
85. Shor, A., Kuo, C.C., and Patton, D.L. (1992) Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 82: 158-161.
86. Summersgill, J.T., Sahney, N.N., Gaydos, C.A., Quinn, T.C., and Ramirez, J.A. (1995) Inhibition of Chlamydia pneumoniae growth in HEp-2 cells pretreated with gamma interferon and tumor necrosis factor alpha. Infect Immun 63: 2801-2803.
87. Summersgill, J.T., Molestina, R.E., Miller, R.D., and Ramirez, J.A. (2000) Interactions of Chlamydia pneumoniae with human endothelial cells. J Infect Dis 181 (Suppl. 3): S479-S482.
88. Vehmaan-Kreula, P., Puolakkainen, M., Sarvas, M., Welgus, H.G., and Kovanen, P.T. (2001) Chlamydia pneumoniae proteins induce secretion of the 92-kDa gelatinase by human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 21: E1-E8.
89. Wilson, P.F.W., D'Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., and Kannel, W.B. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837-1847.